Sagimet Biosciences Inc Series A Common Stock

Sagimet Biosciences Inc Series A Common Stock

Yahoo Finance • 24 days ago

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Inc. FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrot... Full story

Yahoo Finance • last month

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today annou... Full story

Yahoo Finance • 2 months ago

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion

Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple. On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap fo... Full story

Yahoo Finance • 3 months ago

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc... Full story

Yahoo Finance • 4 months ago

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial... Full story

Yahoo Finance • 4 months ago

Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor

MENLO PARK, Calif., May 06, 2026--(BUSINESS WIRE)--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor. Mr. Walbert brings more than three decades... Full story

Yahoo Finance • 4 months ago

Why Sagimet Biosciences Stock Is Soaring Today

Investors had every reason to suspect today's news from Sagimet Biosciences(NASDAQ: SGMT) was coming sooner or later. Nevertheless, seeing the official announcement has clearly proven inspiring. As of 11:40 a.m. ET Monday, SGMT shares are... Full story

Yahoo Finance • 7 months ago

Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Northland upgraded Palantir (PLTR) to... Full story

Yahoo Finance • 9 months ago

Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc... Full story

Yahoo Finance • 9 months ago

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc... Full story

Yahoo Finance • 10 months ago

Sagimet Biosciences GAAP EPS of -$0.40 misses by $0.01

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20305884-sagimet-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate] (SGMT [https://seekingalpha.com/symbol/SGMT]): Q3 GAAP EPS of -$0.40 misse... Full story

Yahoo Finance • 10 months ago

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of... Full story

Yahoo Finance • 11 months ago

Sagimet rises after denifanstat succeeds in late stage trial

[Genetic engineering concept. Medical science. Scientific Laboratory.] metamorworks/iStock via Getty Images * Sagimet Biosciences (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]) announced positive results from a late-stage trial of... Full story

Yahoo Finance • 11 months ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of its pre-NDA consultati... Full story

Yahoo Finance • 11 months ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, toda... Full story

Yahoo Finance • 11 months ago

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero

Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t... Full story

Yahoo Finance • 12 months ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne SAN MATEO,... Full story

Yahoo Finance • last year

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, tod... Full story

Yahoo Finance • last year

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc... Full story

Yahoo Finance • last year

Sagimet Biosciences GAAP EPS of -$0.32 beats by $0.21

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20199186-sagimet-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]): Q2 GAAP EPS of -$0.... Full story